drugset / Trial / NCT00371670

Safety/Efficacy of Balicatib (AAE581) in Adults With Osteoarthritis of the Knee

NCT00371670 ↗

Phase 2 Completed 223 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will test efficacy and safety of AAE581 compared to placebo in limiting cartilage loss in patients with painful knee osteoarthritis which is confirmed by X-ray

Timeline

Start
2004-12
Primary completion
2006-07
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject balicatib Small molecule 10 mg Oral
Subject balicatib Small molecule 25 mg Oral
Subject balicatib Small molecule 50 mg Oral

Indications